

To,

Date: 11.02.2019

- 1) BSE Limited
P.J. Towers, Dalal Street,
Mumbai – 400 001
- 2) Metropolitan Stock Exchange of India Limited
Vibgyor Towers, 4th floor, Plot No. C62, Opp. Trident Hotel,
Bandra Kurla Complex, Bandra (E), Mumbai- 400 098
- 3) Ahmedabad Stock Exchange Limited
Kamdhenu Complex, Opp. Sahajanand College,
Panjara Pole, Ambawadi, Ahmedabad – 380 015

Dear Sir/Madam,

Sub: Outcome of board meeting under regulations 30 read with 33 (3) (c) of SEBI (Listing Obligations and Disclosure requirements) regulations, 2015

Unit: Dr Habeebullah Life Sciences Limited – (Scrip Code: 539267)

With reference to the subject cited, this is to inform the Exchange that meeting of the board of directors of M/s. DR HABEEBULLAH LIFE SCIENCES LIMITED held on Monday, the 11th day of February, 2019 at 3.30 p.m. at the registered office of the company the following were duly considered and approved by the Board:

1. Un-audited financial results for the Quarter ended 31.12.2018.
2. Limited Review Report for the quarter ended 31.12.2018
3. In view of exploring various opportunities for the all-round growth of the company and emerging opportunities in healthcare sector, the Company proposed to incorporate a wholly owned subsidiary of M/s. Dr Habeebullah Life Sciences Limited, in the name & Style of M/s. Krisani Genomics Private Limited or such other name as may be approved by the registrar of companies, Hyderabad.

Un-audited standalone financial results along with Limited Review Report will be uploaded on company's website www.drhisl.com

Furthermore, an extract of the aforesaid Financial Results shall be published in the manner as prescribed under SEBI (LODR) Regulations, 2015.

The meeting of the Board of Directors commenced at 3.30 P.M (IST) and concluded at 5.00 P.M (IST)
This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,

For DR HABEEBULLAH LIFE SCIENCES LIMITED



K. Krishnam Raju

Executive Chairman (DIN 00874690)



PART-I						Rs in Lakhs
STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER III AND 9 MONTHS ENDED 31ST DECEMBER, 2018						
S.No	Particulars	QUARTER ENDED			9 Months ended	
		3 Months ended 31-12-2018	Corresponding 3 months ended in previous year 31-12-2017	Preceding 3 months ended 30-09-2018	9 Months ended 31-12-2018	9 Months ended 31-12-2017
		UnAudited	UnAudited	UnAudited	UnAudited	UnAudited
I	Revenue from Operations	56.05	20.12	52.92	139.44	37.62
II	Other Income	-	-	-	-	-
III	Total Revenue (I+II)	56.05	20.12	52.92	139.44	37.62
IV	Expenses					
	Cost of Material Consumed	5.23	1.31	4.96	13.31	1.87
	Purchase of Stock-in-trade	-	-	-	-	-
	Changes in inventories of finished goods, Work in progress and Stock in trade	-	-	-	-	-
	Employee benefits expense	30.52	19.25	31.29	96.17	59.26
	Finance Costs	-	-	-	-	-
	Depreciation and Amortisation expense	0.09	-	0.09	0.28	-
	Professional Charges	10.57	-	14.43	35.81	-
	Other Expenses	55.77	25.63	60.71	161.33	42.90
	Total Expenses	102.18	46.19	111.48	306.90	104.03
V	Profit/(Loss) from before Exceptional Items and tax (I-IV)	(46.13)	(26.07)	(58.56)	(167.46)	(66.41)
VI	Exceptional Items	-	-	-	-	-
VII	Profit/(Loss) before tax (V-VI)	(46.13)	(26.07)	(58.56)	(167.46)	(66.41)
VIII	Tax Expense:					
	Current Tax	-	-	-	-	-
	Deferred Tax	-	-	-	-	-
IX	Profit/(Loss) for the period from CONTINUING operations (VII-VIII)	(46.13)	(26.07)	(58.56)	(167.46)	(66.41)
X	Profit/ (Loss) from discontinuing operations	-	-	-	-	-
XI	Tax Expense of discontinuing operations	-	-	-	-	-
XII	Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)	-	-	-	-	-
XIII	Profit/ (Loss) for the period (IX+XII)	(46.13)	(26.07)	(58.56)	(167.46)	(66.41)
XIV	Other Comprehensive Income					
	A) (i) Items that will not be reclassified to profit or loss					
	(ii) Income Tax related to items that will not be reclassified to profit or loss					
	B) (i) Items that will be reclassified to profit or loss					
	(ii) Income Tax relating to items that will be reclassified to profit or loss					
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	(46.13)	(26.07)	(58.56)	(167.46)	(66.41)
XVI	Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each)					
	1) Basic	(0.38)	(0.23)	(0.49)	(1.40)	(0.60)
	2) Diluted	(0.32)	(0.23)	(0.40)	(1.15)	(0.60)
XVII	Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each)					
	1) Basic	-	-	-	-	-
	2) Diluted	-	-	-	-	-
XVIII	Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each)					
	1) Basic	(0.38)	(0.23)	(0.49)	(1.40)	(0.60)
	2) Diluted	(0.32)	(0.23)	(0.40)	(1.15)	(0.60)
XIX	Paid Up Equity Share Capital (Face Value of INR 10/ per share)	1,221.37	1105.87	1,221.37	1,221.37	1105.87
XX	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	(142.23)	(190.07)	(142.23)	(142.23)	(190.07)



Notes:

- 1 The Unaudited Standalone financial results for the Quarter III and 9 months period ended 31, December 2018 were reviewed and recommended by the Audit Committee and approved by the Board of Directors at its meeting held on February 11, 2019. The Statutory Auditors have carried out the Limited Review of the Unaudited Standalone Financial Results in accordance with Regulation 33 of SEBI (LODR) Regulations, 2015).
- 2 The Unaudited standalone financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (IND AS) 34 Interim Financial Reporting prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by Securities and Exchange Board of India ("SEBI") and Regulation 33 of SEBI (LODR) Regulations, 2015 and SEBI Circular dated 05th July, 2016.
- 3 Adoption of Ind AS 115 - Revenue from Contracts with Customers
Effective April 1, 2018, the Company has adopted Ind AS 115 "Revenue from Contracts with Customers" using the cumulative catch-up transition method which is applied to contracts that were not completed as of April 1, 2018. Accordingly, the comparatives have not been retrospectively adjusted. The effect on adoption of Ind AS 115 was insignificant on the financial statements.
- 4 The Company has only one reportable segment as per requirements of AS 108 "Operating Segments" i.e., Health Care Sector. Hence, the separate disclosure on Segment information is not required.
- 5 The figures of the corresponding previous period have been regrouped/reclassified wherever necessary, to make them comparable.
- 6 The results are also available on the website of the Company www.drhlsl.com

Place : Hyderabad
Date : 11/02/2019

For DR HABEEBULLAH LIFE SCIENCES LIMITED



K. Krishnam Raju
Executive Chairman (DIN 00874058)



DR HABEEBULLAH LIFE SCIENCES LIMITED

(Formerly known as PC PRODUCTS INDIA LIMITED)

Regd. Office: 2-5-36/CLRD/1, Sy No. 36, Chintalmet X Roads, Upperpally, Rajendra Nagar Mandal, Hyderabad – 500 048, Telangana State, India

Contact No. 040-2970 3333,+91 90300 57370

E-mail id: info@drhsl.com

CIN No : L85110TG1996PLC099198

Website : www.drhsl.com

**EXTRACT OF THE STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER III AND 9 MONTHS ENDED
31ST DECEMBER, 2018**

Rupees in Lacs

Particulars	QUARTER ENDED			Year to Date	
	3 Months ended 31-12-2018	Correspondin g 3 months ended in previous year 31-12-2017	Preceeding 3 months ended 30-09-2018	Year to date for the Current period ended 31- 12-2018	Year to date for the Previous year ended 31-12-2017
	UnAudited	UnAudited	UnAudited	UnAudited	UnAudited
Total income from operations (net)	56.05	20.12	52.92	139.44	37.62
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(46.13)	(26.07)	(58.56)	(167.46)	(66.41)
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	(46.13)	(26.07)	(58.56)	(167.46)	(66.41)
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	(46.13)	(26.07)	(58.56)	(167.46)	(66.41)
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	-	-	-	-	-
Equity Share Capital (Face Value INR 10/- each)	1,221.37	1105.87	1,221.37	1,221.37	1,105.87
Earnings Per Share (for continuing and discontinued operations) (of INR 10/- each)					
Basic	(0.38)	(0.23)	(0.49)	(1.40)	(0.60)
Diluted	(0.32)	(0.23)	(0.40)	(1.15)	(0.60)

Notes:

- The Unaudited Standalone financial results for the Quarter III and 9 months period ended 31, December 2018 were reviewed and recommended by the Audit Committee and approved by the Board of Directors at its meeting held on **February 11, 2019**. The Statutory Auditors have carried out the Limited Review of the Unaudited Standalone Financial Results in accordance with Regulation 33 of SEBI (LODR) Regulations, 2015).
- The Unaudited standalone financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (IND AS) 34 Interim Financial Reporting prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by Securities and Exchange Board of India ("SEBI") and Regulation 33 of SEBI (LODR) Regulations, 2015 and SEBI Circular dated 05th July, 2016.
- The Company has only one reportable segment as per requirements of AS 108 "Operating Segments" i.e., Health Care Sector. Hence, the separate disclosure on Segment information is not required.
- The figures of the corresponding previous period have been regrouped/reclassified wherever necessary, to make them comparable.
- The above is an extract of the detailed format of the Standalone Statement of Unaudited Financial Results filed with the Stock Exchanges under Reg. 33 of SEBI (LODR) Regulations, 2015. The Complete Financial Results are available on the Websites of BSE Limited (www.bseindia.com), MSEI Limited (www.mcx-scx.com), ASE Limited (www.aselindia.com) and on the Company's Website www.drhsl.com

Place : Hyderabad

Date : 11/02/2019



For DR HABEEBULLAH LIFE SCIENCES LIMITED

K. Krishnam Raju
K. Krishnam Raju

Executive Chairman (DIN 00874630)



Limited Review Report

**Review Report to
The Board of Directors
DR HABEEBULLAH LIFE SCIENCES LIMITED**

1. We have reviewed the accompanying statement of unaudited standalone financial results of DR HABEEBULLAH LIFE SCIENCES LIMITED ('the Company') for the quarter ended 31st December, 2018 and the year to-date results for the period 1st April 2018 to 31st December, 2018, (the Statement), being submitted by the Company pursuant to the requirements of Regulation 33 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 and Regulation 52 as modified by Circular No. CIR/IMD/DF1/69/2016 dated August 10, 2016 read with Regulation 63(2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations). This Statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with Ind AS 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone financial results and financial position which are prepared in accordance with Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For MSKA & Associates
Chartered Accountants
ICAI Firm Registration No.105047W



Ananthakrishnan G
Partner
Membership No.:205226



Place: Hyderabad
Date: 11th February 2019